Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
June 2, 2020

Covid-19’s impact on trial PROs, other endpoints can be addressed via data stratification, sensitivity analysis

By Victoria Smith

The Covid-19 pandemic has left pharmaceutical companies, particularly those in the psychiatry space, contending to learn the disaster’s impact on patient-reported outcomes (PROs) utilised in studies and similar subjective measures that calculate patient or caregiver emotions.

To salvage PROs, as well as other results for studies in any therapeutic area that started before the beginning of the pandemic, clients are advised to translate data collected pre-, during and post-Covid-19, as well as conduct sensitivity analysis. Read more here.

Related Companies

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy